---
title: "BIOADAPTIVES 2025 10-K: Revenue $18,278, EPS $(0.15)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282740176.md"
description: "BIOADAPTIVES reported revenue of $18,278 for 2025, with a net loss of $(1,557,898) and EPS of $(0.15). Despite a gross profit increase to $12,497, losses from operations widened due to higher expenses. The company is focusing on product development and marketing, with minimal revenue growth and strategic repositioning. New product rollouts are expected in Q2 2025, supported by ongoing clinical trials. The company also completed a reverse stock split and approved a stock dividend."
datetime: "2026-04-14T20:15:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282740176.md)
  - [en](https://longbridge.com/en/news/282740176.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282740176.md)
---

# BIOADAPTIVES 2025 10-K: Revenue $18,278, EPS $(0.15)

BIOADAPTIVES reported modest revenue of $18,278 for the year, with a net loss of $(1,557,898) and net loss per common share of $(0.15), reflecting higher operating expenses and intensified investment in product development and marketing. Gross profit improved to $12,497 versus $4,030 in 2024, but loss from operations widened to $(1,042,173) as operating expenses increased to $1,054,670. The results reflect limited sales activity alongside strategic repositioning of the product portfolio and go-to-market preparations.

**Financial Highlights**

-   **Revenue**: $18,278 (increase from $12,669 in 2024)
-   **Gross Profit**: $12,497 (improved vs $4,030 in 2024)
-   **Loss from operations**: $(1,042,173) (operating expense increase to $1,054,670)
-   **Net Loss**: $(1,557,898) (worsened from $(899,161) in 2024)
-   **Net Loss Per Common Share**: $(0.15) (vs $(0.11) in 2024)

**Business Highlights**

-   **Revenue Growth**: Minimal revenue increase to $18,278 in 2025 from $12,669 in 2024, reflecting very limited sales activity.
-   **Product Pipeline & Branding**: Reformulating the full product line with pre-launch activities for MyndMed™, PawPa® Regen, Xcellara™, and Zeranovia™ to build brand presence.
-   **Channel Expansion**: Executed a marketing agreement and acquired inventory for the FDA-cleared Lung Flute™ with plans to target medical, pharmacy, fitness, and senior channels.
-   **Operational Milestones**: Completed a reverse split (1-for-300) and approved a one-for-one stock dividend; leadership transition to CEO James Kneer occurred in 2024.
-   **Go-to-Market Timing**: New product rollouts expected beginning in Q2 2025, supported by ongoing clinical trials and market testing.

Original SEC Filing: BIOADAPTIVES, INC. \[ BDPT \] - 10-K - Apr. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AADI.US](https://longbridge.com/en/quote/AADI.US.md)
- [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)